|
|
Article: PowderJect DNA Vaccine First to Achieve Protective Immunity in Non-Responders To Commercial Vaccine.
- Article from:
- PR Newswire
- Article date:
- April 24, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
OXFORD, England, FREMONT, Calif., and MADISON, Wis., April 24 /PRNewswire Interactive Press Release/ -- PowderJect Pharmaceuticals Plc (London: PJP) and its wholly owned subsidiary, PowderJect Vaccines Inc., today announced the first achievement of protective immunity by a DNA vaccine in volunteers who do not respond to current commercial vaccines. The preliminary data from the hepatitis B DNA vaccine clinical study will be presented today at the Fourth Annual Conference on Vaccine Research in Arlington, VA by the clinical investigator, Dr. Gregory A. Poland of the Mayo Clinic. The study is part of PowderJect's major DNA vaccine collaboration with GlaxoSmithKline.
...